Vaxelis suspension inyectable en jeringa precargada
How to use Vaxelis suspension inyectable en jeringa precargada
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Prospecto: information for the user
Vaxelis pre-filled syringe suspension
Diphtheria, tetanus, pertussis (acellular component), hepatitis B (rDNA), inactivated poliomyelitis, and Haemophilus b conjugate (adsorbed) vaccine
Read this prospectus carefully before your child is vaccinated with this medicine as it contains important information for you.
- Keep this prospectus as you may need to read it again.
- If you have any doubts, consult your doctor, pharmacist, or nurse.
- This medicine has been prescribed only for your child, and it should not be given to other people.
- If your child experiences adverse effects, consult your doctor, pharmacist, or nurse even if they are not listed in this prospectus.See section4.
1.What Vaxelis is and for what it is used
2.What you need to know before Vaxelis is administered to your child
3.How to use Vaxelis
4.Possible adverse effects
5.Storage of Vaxelis
6.Contents of the package and additional information
1. What is Vaxelis and what is it used for
Vaxelis is a vaccine that helps protect your child against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and serious diseases caused byHaemophilus influenzaetype b. Vaxelis is administered to children from six weeks of age.
The vaccine works by causing the body to generate its own protection (antibodies) against the bacteria and viruses that cause the following diseases:
- Diphtheria: a bacterial infection that usually affects the throat first, causing pain and swelling that can lead to asphyxiation. The bacteria also produce a toxin (poison) that can damage the heart, kidneys, and nerves.
- Tetanus: caused by the penetration of the tetanus bacteria into a deep wound. The bacteria produce a toxin (poison) that causes muscle spasms, leading to an inability to breathe and the possibility of asphyxiation.
- Pertussis (also known as whooping cough): a highly contagious disease that affects the respiratory tract. This causes severe coughing attacks that can lead to respiratory problems. The coughing attacks often feature a distinctive "whooping" sound. Pertussis can last from one to two months or more. It can also cause ear infections, bronchitis, which can last a long time, pneumonia, convulsions, brain damage, and even death.
- Hepatitis B: caused by the hepatitis B virus. This causes the liver to become inflamed (inflammation). In some people, the virus can remain in the body for a long time, and eventually can cause serious liver problems, including liver cancer.
- Poliomyelitis (also known as polio): caused by viruses that affect the nerves. It can lead to muscle paralysis or weakness, most often in the legs. Paralysis of the muscles that control breathing and swallowing can be fatal.
- Haemophilus influenzae type b infections (often simply called Hib infections): severe bacterial infections that can cause meningitis (inflammation of the membranes that surround the brain), which can cause brain damage, hearing loss, epilepsy, or partial blindness. The infection can also cause inflammation and swelling of the throat, making it difficult to swallow and breathe, and can affect other parts of the body, such as the blood, lungs, skin, bones, and joints.
Important information about the protection provided
- Vaxelis will only help prevent these diseases if they are caused by the bacteria and viruses for which the vaccine is intended. Vaxelis does not protect your child against diseases caused by other bacteria and viruses that could cause similar symptoms.
- The vaccine does not contain any living bacteria or viruses and cannot cause any of the infectious diseases against which it protects.
- Like any vaccine, Vaxelis may not protect 100% of vaccinated children.
2. What you need to know before Vaxelis is administered to your child
In order to ensure that Vaxelis is suitable for your child, it is essential that you inform your doctor or nurse if your child presents any of the characteristics detailed below. If you do not understand anything, consult your doctor, pharmacist, or nurse.
Do not use Vaxelis if your child:
- has had difficulty breathing or swelling of the face (anaphylactic reaction) after a previous dose of Vaxelis.
- is allergic (hypersensitive)
- to the Vaxelis vaccine or to any other vaccine that contains diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, or Hib,
- to any of the other components included in section 6,
- to glutaraldehyde, formaldehyde, neomycin, streptomycin, polymyxin B (antibiotics), andbovine serum albumin,since these substances are used during the manufacturing process,
- has suffered a severe reaction affecting the brain (encephalopathy) within 7 days after administration of a previous dose of a pertussis vaccine (acellular or whole-cell).
- has an uncontrolled disease or severe disease affecting the brain and nervous system (uncontrolled neurological disorder) or uncontrolled epilepsy.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before vaccination, if your child:
- has a moderate to severe acute illness, with or without fever (e.g. sore throat, cough, cold, or flu). It may be possible to postpone vaccination until your child feels better.
- has experienced any of the following adverse events after receiving a pertussis vaccine, they should be carefully evaluated to decide whether to administer other doses of vaccine containing the pertussis component:
- fever of 40.5°C or higher within 48hours, not due to another identifiable cause.
- weakness, loss of sensation, or loss of consciousness, after previous vaccination, within 48hours after vaccination.
- continuous crying and could not be comforted for 3hours or more, within 48hours after vaccination.
- attacks (convulsions) with or without fever, within 3days after vaccination.
- has previously experienced Guillain-Barré syndrome (temporary loss of sensation and movement) after administration of a vaccine containing tetanus toxoid (a form of inactivated tetanus toxoid). Your doctor will evaluate the decision to administer Vaxelis to your child.
- is receiving treatment (such as steroids, chemotherapy, or radiation therapy) or has a diseasethat suppressesor weakensthe body's abilityto fight infections.It is recommendedto postponethe vaccinationuntil the end ofsuch treatment ordisease. However, children with long-term problems with their immune system, such as HIV (AIDS), may be given Vaxelis, but the protection may not be as good as in children with a healthy immune system.
- has an undiagnosed brain disease or uncontrolled epilepsy. Your doctor or nurse will evaluate the potential benefit of vaccination once the disease is stabilized.
- has seizures when feverish, or has a family history ofseizuresthat occurwhen feverish.
- has any bleeding disorder, such as prolonged bleeding after minor cuts or easy bruising. Your doctor will advise you on whether to administer Vaxelis to your child.
- was bornveryprematurely(before28 weeksof gestation).In these children, there may be longer than usual pauses between breaths for 2 to 3daysafter vaccination.
Other medications or vaccines and Vaxelis
Inform your doctor or nurse if your child is using, has used recently, or may need to use any other medication or vaccine.
Vaxelis can be administered at the same time as other vaccines such as pneumococcal vaccines, MMRV vaccines (measles, mumps, rubella, and varicella), rotavirus vaccines, or meningococcal B or C vaccines.
Your doctor or nurse will administer these injections in different injection sites andwill usedifferentneedlesand syringesfor each injection.
Driving and operating machinery
It is expected that the influence of Vaxelis on the ability to drive and operate machinery will be negligible or insignificant.
Vaxelis contains sodium
This medicine contains less than 1mmol of sodium (23mg) per dose; this is, essentially “sodium-free”.
3. How to use Vaxelis
Vaxelis will be administered to your child by a doctor or nurse who is properly trained in the use of vaccines and equipped to react to any rare severe allergic reaction that may occur after the injection (see section4 “Possible side effects”).
Your doctor or nurse will inject Vaxelis into your child's thigh (in babies from 6weeks of age) or arm (in children over one year old).
The recommended dose is as follows:
Primary vaccination cycle (primary vaccination)
Your child will receivetwo orthree injections administered at least one month apart.Your doctoror nurse will inform you whenyour child should return forthenextinjection according to the local vaccination schedule.
Additional injection (booster vaccination)
After the primary vaccination cycle, your child will receive a booster dose, according to local recommendations, at least 6months after the last dose of the primary vaccination cycle. Your doctor will advise you on when to administer this dose.
If your child did not receive a dose of Vaxelis
If by mistake, your child does not receive a scheduled injection, it isimportant to inform your doctor ornurse, they will decide when to administer the missed dose.
It isimportant to follow the doctor'sor nurse's instructions for your child to complete the vaccination cycle. Otherwise, your child may not be fully protected against diseases.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
4. Possible Adverse Effects
Like all medicines, this vaccine may cause side effects, although not everyone will experience them.
Severe allergic reactions
If any of these symptoms occur after leaving the place where your child received the injection, you should consult a doctor IMMEDIATELY:
- difficulty breathing
- blue discoloration of the tongue or lips
- eruption
- swelling of the face or throat
- low blood pressure causing dizziness or collapse.
These signs and symptoms usually develop rapidly after the injection and while the child is still at the clinic or medical consultation.
Severe allergic reactions are very rare (may affect up to 1 in 10,000 people) and can occur after receiving a vaccine.
Other side effects
If your child experiences any of the following side effects, consult your doctor, nurse or pharmacist.
- Very common side effects (may affect more than 1 in 10 people) are:
- decreased appetite
- irritability
- crying
- vomiting
- drowsiness or somnolence
- fever (temperature of 38°C or higher)
- pain, redness, swelling at the injection site
- Common side effects (may affect up to 1 in 10 people) are:
- diarrhea
- hard lump, nodule at the injection site
- redness at the injection site
- Uncommon side effects (may affect up to 1 in 100 people) are:
- eruption
- heat, eruption at the injection site
- increased appetite
- stomach pain
- excessive sweating
- cough
- nasal congestion and discharge
- pallor
- sleep disturbances, includingthe inability to get a good night's sleep
- restlessness
- inflammation of the lymph nodes in the neck, armpit or groin
- sensation of fatigue
- weakness (hypotonia)
- Rare side effects (may affect up to 1 in 1,000 people) are:
- allergic reaction, severe allergic reaction (anaphylactic reaction)
- extensive swelling of the vaccinated limb
- Side effects with unknown frequency (cannot be estimated from available data) are:
- seizures (convulsions) with or without fever
- weakness and loss of sensation or loss of consciousness and/or pallor or blue skin
Other side effects not mentioned earlier have been reported with other vaccines that contain diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B or Hib:
- episodes ofshockor pallor, weaknessand loss of sensation
Reporting of side effects
If your child experiencesany type ofside effect, consult your doctor, pharmacist or nurse, even if it is a possible side effect that does not appear in this prospectus.You can also report them directly through thenational notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
5. Conservation of Vaxelis
Keep this medication out of the sight and reach of children.
Store in refrigerator (between 2°C and 8°C). Do not freeze. Store the container in the outer packaging to protect it from light.
Do not use this vaccineafter the expiration date that appears on the label and the box after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medicines that you no longer need. In this way, you will help protect the environment.
6. Contents of the packaging and additional information
Composition of Vaxelis
The active principles per dose (0.5ml) are:
Diphtheria toxoid1 | not less than 20 IU6 |
Tetanus toxoid1 | not less than 40 IU6 |
Antigens ofBordetella pertussis1 | |
Pertussis toxoid (PT) | 20 micrograms |
Filamentous hemagglutinin (FHA) | 20 micrograms |
Pertactin (PRN) | 3 micrograms |
Fimbriae type 2 and 3 (FIM) | 5 micrograms |
HBsAg (Hepatitis B surface antigen)23 | 10 micrograms |
Inactivated poliovirus4 | |
Type 1 (Mahoney) | 40 antigen units D5 |
Type 2 (MEF-1) | 8 antigen units D5 |
Type 3 (Saukett) | 32 antigen units D5 |
Polysaccharide ofHaemophilus influenzaetype b | |
(polyribosylribitol phosphate) | 3 micrograms |
Conjugated with meningococcal protein2 | 50 micrograms |
1adsorbed on aluminium phosphate (0.17mg Al3+)
2adsorbed on amorphous aluminium hydroxiphosphate sulphate (0.15mg Al3+)
3produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
4produced in Vero cells
5or equivalent antigenic amount in the vaccine determined by an appropriate immunochemical method
6or equivalent activity determined by an immunogenicity evaluation.
Aluminium phosphate andamorphous aluminium hydroxiphosphate sulphateare included in the vaccine as adjuvants.The adjuvants are included toimprove the immune response of the vaccines.
The other components are:
Sodium phosphate and water for injections.
The vaccine may contain traces ofglutaraldehyde, formaldehyde, neomycin, streptomycin, polymyxin B andbovine serum albumin.
Appearance of the product and contents of the pack
The normal appearance of the vaccine is a uniform, turbid white to off-white suspension, which maysedimentduring storage.
Vaxelis is supplied as a pre-filled syringe injection.
Size of pack: 1, 10pre-filled syringes without a fixed needle, with 1separate needle or 2separate needles.
Multi-pack of 5packs, each containing 10pre-filled syringes without a fixed needle.
Only some pack sizes may be commercially available.
Marketing authorization holder and manufacturer responsible
MCM Vaccine B.V., Robert Boyleweg 4, 2333 CG Leiden,Netherlands
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien MSD Belgium Tel/Tel: +32(0)27766211 | Lietuva UAB Merck Sharp & Dohme Tel. + 370 5 278 02 47 |
Luxembourg/Luxemburg MSD Belgium Tél/Tel: +32(0)27766211 | |
Ceská republika Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 | Magyarország MSD Pharma Hungary Kft. Tel.: +36 1 888 5300 |
Danmark MSD Danmark ApS Tlf.: + 45 4482 4000 | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) |
Deutschland MSD Sharp & Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 0) | Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) |
Eesti Merck Sharp & Dohme OÜ Tel.: +372 6144 200 | Norge MSD (Norge) AS Tlf: +47 32 20 73 00 |
Ελλ?δα MSDΑ.Φ.Ε.Ε. Τηλ: +30 210 98 97 300 | Österreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com |
España Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 | Polska MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 |
France MSD France Tél: + 33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 |
Hrvatska Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 | România Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 | Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 5204 201 |
Ísland | Slovenská republika Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 |
Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) | Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804 650 |
Κ?προς Merck Sharp & Dohme Cyprus Limited Τηλ.: 800 00 673 (+357 22866700) cyprus_info@merck.com | Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 |
Latvija SIA Merck Sharp & Dohme Latvija Tel: + 371 67364224 msd_lv@merck.com | United Kingdom (Northern Ireland) Sanofi Tel: +44 845 372 7101 |
Last update of this leaflet:{month} {year}.
For detailed information about this medicinal product, please visit the website of the European Medicines Agency:https://www.ema.europa.eu.
This leaflet is available in all languages of the European Union/European Economic Area on the website of the European Medicines Agency.
---------------------------------------------------------------------------------------------------------------------------
This information is intended for healthcare professionals only:
The pre-filled syringe should be gently agitated to obtain a uniform, white to off-white, opaque suspension.
Visually inspect the suspension before administration to detect any foreign particles and/or physical aspect variations. In case of observing any of these circumstances, discard the pre-filled syringe.
The needle should be firmly attached to the syringe, rotating it by a quarter of a turn.
Vaxelis is only for intramuscular injection.
The recommended injection sites are the antero-lateral area of the thigh or the upper deltoid muscle of the arm if there is sufficient muscle mass. The antero-lateral area of the thigh is the recommended site for infants under one year of age.
- Country of registration
- Dosage formSuspension for injection in pre‑filled syringe, Greater than or equal to 20 IU/Greater than or equal to 40 IU/20 µg/20 µg/3 µg/5 µg/40 U.D. (UNITS OF ANTIGENIC D)/8 U.D. (UNITS OF ANTIGENIC D)/32 U.D. (UNITS OF ANTIGENIC D)/10 µg/3 µg
- ATC codeJ07CA09
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to Vaxelis suspension inyectable en jeringa precargadaDosage form: INJECTABLE, 0.5 mLManufacturer: Sanofi Winthrop IndustriePrescription requiredDosage form: INJECTABLE, 0.5 mlManufacturer: Sanofi Winthrop IndustriePrescription requiredDosage form: INJECTABLE, 0.5 mlManufacturer: Sanofi Winthrop IndustriePrescription required
Online doctors for Vaxelis suspension inyectable en jeringa precargada
Discuss questions about Vaxelis suspension inyectable en jeringa precargada, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
